On Thursday, in the course of current trade, Shares of Hilton Worldwide Holdings Inc (NYSE:HLT), dropped -2.97%, and is now trading at $27.16.
Offering the perfect blend of modern luxury and storied history, Anselmo Buenos Aires joined Curio – A Collection by Hilton. As Hilton Worldwide’s (HLT) rapidly-expanding global collection of distinctive hotels, Curio caters to passionate travelers seeking local discovery and authentic experiences. Located in Buenos Aires’ historic neighborhood of San Telmo, Anselmo Buenos Aires is set amid Plaza Dorrego Square, one of the oldest public spaces in the city known for its diverse array of cafés, bars, shops and antique stores.
“Originally built as a stunning mansion in 1906, Anselmo Buenos Aires pays tribute to a community rich in history that dates back to the 18th century, and provides guests with the perfect launching pad for a truly intriguing cultural experience,” said Dianna Vaughan, global head, Curio – A Collection by Hilton. “As a hotel that honors its proud past while also celebrating modern luxury that today’s savvy traveler has come to expect, we’re honored to welcome this beautiful property to our collection, and as our first hotel in Latin America.”
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations.
During an Afternoon trade, Shares of Target Corporation (NYSE:TGT), dipped -0.86%, and is now trading at $82.08.
Target Corporation says it had no intention of offending anyone by selling a women’s shirt with the word “Trophy” written on the front of it, according to AP.
Some people on social media say the shirt demeans women and are collecting signatures to stop the sale of the shirt.
But Target said Wednesday that the shirt is part of a collection of engagement and wedding shirts that also comprises shirts with sayings such as “Team Bride,” ”Mrs.” and “Bride.” AP Reports.
The Minneapolis company said in a written statement that it was never its intention to offend anyone and said that it has received an “overwhelmingly positive” response from customers about the shirts. AP added.
Target Corporation operates as a general merchandise retailer in the United States and Canada. It offers household essentials, counting pharmacy, beauty, personal care, baby care, cleaning, and paper products; music, movies, books, computer software, sporting goods, and toys; electronics, such as video game hardware and software; and apparel for women, men, boys, girls, toddlers, infants, and newborns, in addition to intimate apparel, jewelry, accessories, and shoes.
Shares of Mastercard Inc (NYSE:MA), during its Thursday’s current trading session fell -1.58%, and is now trading at $95.35.
MasterCard opened its digital security facility to its customers, driving further partnershipon key issues that can deliver greater payments peace of mind. Located in England, the MasterCard DigiSec Lab is focused on proactively testing threats to all forms of digital payments in coordination with government security agencies and leading academics. For more information on the DigiSec Lab, please read our full press release.
“The MasterCard DigiSec Lab represents our collective efforts to maximize product innovation and security investments,” said Ajay Bhalla, president of Enterprise Security Solutions at MasterCard. “While payments have never been safer, criminals have never been smarter. We’ve now opened the lab to our customers as part of an ongoing commitment to share insights, solutions, and best practices to deliver the highest levels of security.”
MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services. It also offers value-added services, such as loyalty and reward programs, and information and consulting services.
Finally, Dynavax Technologies Corporation (NASDAQ:DVAX), lost -2.76% Thursday.
Dynavax Technologies Corporation, declared the pricing of a formerly declared underwritten public offering of 4,545,455 shares of its common stock, offered at a price to the public of $27.50 per share. The gross proceeds to Dynavax from this offering are predictable to be about $125 million, before deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 681,818 additional shares of its common stock to cover over-allotments, if any. The offering is predictable to close on or about July 27, 2015, subject to customary closing conditions. Dynavax anticipates using the net proceeds from the projected offering to fund activities associated with concluding the ongoing Phase 3 HBV-23 study of HEPLISAV-B™, seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support ongoing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, counting working capital.
Cowen and Company, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
